Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GDC-0134 in ALS
NCT02655614Phase 1Completed
- Sponsor
- Genentech
- Start
- May 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of GDC-0134 in amyotrophic lateral sclerosis (ALS) (5 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events (AEs) at 48 months, Percentage of Participants With Clinically Significant Laboratory Abnormalities at 48 months and 3 more. Started May 2016; status: completed.
02
Drugs
GDC-0134
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02655614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655614.